Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports

NEXT STORY
BioVie Advances the BIV201 Clinical Program and Prefilled Syringe
PREV STORY
2020 Outlook on the Worldwide COVID-19 Market – Events That Pushed Share Prices Up
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports

NEXT STORY
BioVie Advances the BIV201 Clinical Program and Prefilled Syringe
PREV STORY
2020 Outlook on the Worldwide COVID-19 Market – Events That Pushed Share Prices Up
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Biomarker Data Supports Direct Link between VB-111’s Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme Patients

TEL AVIV, Israel, Dec. 18, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), announced new ...

author_avatar
NASDAQ Market News

Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available

GAITHERSBURG, May 04, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that ...

author_avatar
NASDAQ Market News

Affimed Announces Pipeline and Business Update

author_avatar
NASDAQ Market News